重组凝血因子VIIa与小儿心脏手术血栓并发症增加相关
该回顾性研究采用倾向评分匹配,比较围术期接受重组凝血因子VIIa(rFVIIa)的儿童心脏手术患者与匹配对照者的血栓并发症发生率。结果显示rFVIIa组血栓并发症发生率显著增高(20% vs 8%;OR 3.9,95%CI 2.6-5.9,P < .001),但30天死亡率无差异。结论认为rFVIIa在小儿心脏手术中应极其谨慎使用。
要点
- rFVIIa与小儿心脏手术后血栓并发症风险增加约4倍相关
- rFVIIa组心脏ICU和住院时间均显著延长
- 再探查止血和30天死亡率两组无显著差异
核心结论
- 围术期使用rFVIIa与小儿心脏手术后血栓并发症发生率增加相关,但未增加30天死亡率。
- rFVIIa在小儿心脏手术患者中应极其谨慎使用。
研究设计与样本
- 回顾性研究,纳入2011年5月1日至2013年10月31日在波士顿儿童医院接受先天性心脏病手术的新生儿和儿童。
- 使用倾向评分匹配,纳入10个与术后出血相关的因素,将rFVIIa患者与2名对照匹配。
- 最终分析纳入143例rFVIIa患者和283例对照患者。
主要发现
- rFVIIa组血栓并发症发生率为20%,对照组为8%(OR 3.9,95%CI 2.6-5.9,P < .001)。
- rFVIIa组心脏ICU停留时间中位数为8天(IQR 4-24),对照组为5天(IQR 2-10),P < .001。
- rFVIIa组住院时间中位数为20天(IQR 9-44),对照组为11天(IQR 7-23),P < .001。
- 因出血再探查率两组无显著差异(rFVIIa组14% vs 对照组9%;OR 1.7,95%CI 0.92-3.1,P = .12)。
- 30天死亡率两组无显著差异(rFVIIa组8% vs 对照组6%;OR 1.3,95%CI 0.60-2.89,P = .51)。
临床怎么用
- 在小儿心脏手术围术期使用rFVIIa作为止血药时,需高度警惕血栓并发症风险。
- 使用rFVIIa前应权衡血栓风险与出血风险,并密切监测血栓事件。
局限性
- 回顾性研究设计。
- 单中心研究。
- 可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recombinant factor VIIa (rFVIIa) is routinely used as an off-label hemostatic agent in children undergoing cardiac surgery. Despite evidence that rFVIIa use is associated with an increased incidence of thrombotic complications in adult cardiac surgery, the safety of rFVIIa as a rescue hemostatic agent in the pediatric cardiac surgical population is less definitively delineated. In this retrospective study, we used propensity score matching to compare the incidence of thrombotic complications between children treated with rFVIIa and their matched controls. METHODS: We retrospectively reviewed medical records and pharmacy data from all neonates and children who underwent congenital cardiac surgery between May 1, 2011, and October 31, 2013, at Boston Children's Hospital, and identified those who received rFVIIa during the perioperative period. Using existing knowledge, we chose 10 factors associated with bleeding after cardiac surgery to be used in our propensity score: age, sex, body weight, neonates, prematurity, previous sternotomy, cardiopulmonary bypass time, deep hypothermic circulatory arrest time, aortic cross-clamp time, and the operative surgeon. We then used propensity-matched analysis to match children treated with rFVIIa with 2 controls. The primary outcome was thrombotic complications. Secondary outcomes included reexploration for bleeding, length of cardiac intensive care unit stay, length of hospital stay, and 30-day mortality. RESULTS: One hundred forty-nine patients received perioperative rFVIIa during the study period. Propensity matching yielded 143 rFVIIa patients matched to 2 control patients each (n = 286). Three control patients were found to have received rFVIIa during the perioperative course and were removed from the analysis, for a total of 283 control patients. The administration of rFVIIa was associated with an increased incidence of thrombotic complications (20% vs 8%; odds ratio [OR]: 3.9 [95% confidence interval {CI}: 2.6-5.9], P < .001). Administration of rFVIIa was associated with a prolonged median length of cardiac intensive care unit stay (8 days [interquartile range {IQR}: 4-24] vs 5 days [IQR: 2-10], P < .001) and prolonged length of hospital stay (20 [IQR: 9-44] vs 11 days [IQR: 7-23], P < .001). No difference in reexploration for bleeding (rFVII = 14% vs controls = 9%; OR: 1.7 [95% CI, 0.92-3.1], P = .12) or 30-day mortality was observed (8% vs 6%; OR 1.3 [95% CI, 0.60-2.89], P = .51). CONCLUSIONS: This retrospective analysis confirmed that perioperative administration of rFVIIa is associated with an increased incidence of postoperative thrombotic complications in neonates and children undergoing cardiac surgery, without increase in 30-day mortality. In conclusion, rFVIIa should be used with extreme caution in pediatric patients undergoing cardiac surgery.
引用
- Downey L, Brown ML, Faraoni D, et al. Recombinant Factor VIIa Is Associated With Increased Thrombotic Complications in Pediatric Cardiac Surgery Patients. Anesth Analg. 2017. PMID: 28319507. doi:10.1213/ANE.0000000000001947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。